SCHEMBL8302875

SCHEMBL8302875

CCC(CC)c1ccc(Oc2ccc(C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD4 Q15561 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
FNTA P49354 2/20 0.43
FNTB P49356 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ACHE P22303 1/20 0.39
MMP13 P45452 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HTT P42858 1/20 0.39
MMP14 P50281 1/20 0.38
ESR1 P03372 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3989199 0.87 ADRA2A (0.48) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL10695265 0.78 TEAD4 (0.52) TEAD4ALDH1A1MAPTPOLBTDP1
SCHEMBL83814 0.76 TEAD4 (0.74) TEAD4ALDH1A1MAPTPOLBTDP1
SCHEMBL83863 0.76 TEAD4 (0.74) TEAD4ALDH1A1MAPTPOLBTDP1
SCHEMBL95343 0.76 TEAD4 (0.74) TEAD4ALDH1A1MAPTPOLBTDP1
SCHEMBL21656832 0.76 SRD5A2 (0.58) MAPTKMT2AHDAC8HDAC6
SCHEMBL21656852 0.76 CA12 (0.53) ALDH1A1MAPTPOLBTDP1MEN1
SCHEMBL10030396 0.76 TEAD4 (0.60) TEAD4ALDH1A1MAPTPOLBTDP1
SCHEMBL4705880 0.76 FFAR1 (0.53) ALDH1A1MAPTTDP1ACHE
SCHEMBL18409817 0.76 TEAD4 (0.54) TEAD4ALDH1A1MAPTPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005009392-A2 DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-03 WO disclosed